Pfizer Inc. (NYSE:PFE) Announces Quarterly Dividend of $0.43

Pfizer Inc. (NYSE:PFE) announced a quarterly dividend on Wednesday, June 24th. Stockholders of record on Friday, July 24th will be given a dividend of 0.43 per share by the biopharmaceutical company on Tuesday, September 1st. This represents a c) annualized dividend and a dividend yield of 7.2%. The ex-dividend date of this dividend is Friday, July 24th.

Pfizer has decreased its dividend by an average of 0.1%annually over the last three years and has raised its dividend annually for the last 16 consecutive years. Pfizer has a dividend payout ratio of 55.8% indicating that its dividend is sufficiently covered by earnings. Analysts expect Pfizer to earn $2.86 per share next year, which means the company should continue to be able to cover its $1.72 annual dividend with an expected future payout ratio of 60.1%.

Pfizer Price Performance

Shares of PFE opened at $24.05 on Thursday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The company’s fifty day moving average price is $26.07 and its 200-day moving average price is $26.31. Pfizer has a 1-year low of $23.11 and a 1-year high of $28.75. The firm has a market capitalization of $137.07 billion, a PE ratio of 18.36 and a beta of 0.34.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the business posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts predict that Pfizer will post 2.99 EPS for the current year.

Institutional Investors Weigh In On Pfizer

Hedge funds have recently modified their holdings of the company. Vermillion Wealth Management Inc. boosted its position in Pfizer by 19.4% during the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 382 shares in the last quarter. Triad Wealth Partners LLC lifted its position in shares of Pfizer by 1.9% during the 4th quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after buying an additional 386 shares in the last quarter. Eagle Capital Management LLC grew its stake in Pfizer by 0.3% in the 1st quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock valued at $3,554,000 after acquiring an additional 390 shares during the period. ETF Store Inc. grew its stake in Pfizer by 3.8% in the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after acquiring an additional 396 shares during the period. Finally, Delta Financial Advisors LLC increased its holdings in Pfizer by 1.6% in the 1st quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock worth $709,000 after acquiring an additional 398 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.